Effect of Intrahepatic Arterial Delivery of Sorafenib on Normal Liver Tissue of Rabbit: An Experimental Study

Source:
By:Eerdunbagena ning

DOI: https://doi.org/10.30564/jams.v3i1.1468

Abstract:

Objective: To assess the safety, feasibility and eluting efficiency of intrahepatic arterial delivery of sorafenib on normal liver tissue of rabbit. Methods: 24 New Zealand rabbits were randomly divided into three groups: group Ⅰ (Lipiodol-sorafenid), group Ⅱ (Lipiodol) and group Ⅲ (Sorafenib). Group Ⅰ and Ⅱ were treated by transcatheter selective hepatic arterial embolization with emulsions of lipiodol and sorafenib or with only lipiodol, while group Ⅲ was given hepatic arterial infusion with sorafenib. Sorafenib concentration in plasma was determined by HPLC (high performance liquid chromatography) in 0 min, 20 min, 1h, 2h, 4h, 8h, 16h, 32h and 48h respectively. The breathing rate, heart rate, rectal temperature and body weight were measured, as well the blood routine test and the function of liver, kidney, and heart. Two animals of each group were respectively killed in the 3^rd day, 1^st, 3^rd and 6^th week after treatment. Histopathologic study was done to liver, heart, kinney, lung, brain, gall bladder and intestine. Result: ① The peak sorafenib concentration (Cmax)and AUC(Area under curve) in plasma in groupⅠwas 2.46±0.101μg/ml and 945.72 ± 52.3 μg/mL.min respectively, while in group Ⅲ which was 3.78±0.180 ug/ml and 546.98±21.1μg/mL.min. Compared with groupⅢ, the Cmax and AUC of groupⅠhad a significant statistics difference (p<0.05). ② The breathing rate, heart rate, rectal temperature and AST/ALT,WBC,NEU% of group Ⅰand groupⅢhas a significant statistics difference(p<0.05) in the 3^rd day. ③CK ,CK-MB, DB, Cr，BUN,RBC,PLT in plasma did not change in all group.④Local necrosis was seen in group Ⅰand group Ⅱin the 3^rd day and 1^st week, but they did not seem to be different. Group Ⅲ showed no necrosis. Granulation tissue with bile duty, portal vein and microfossils hyperplasia were seen in local necrosis area in the 3^rd week. No pathological changes were found in brain, heart, kidney, intestine and gallbladder. Conclusion: TAE with emulsions of lipiodol and sorafenib is feasible, safe and has some slow-release effect.

References:

[1]Virmani S, Rhee TK, Ryu RK,et al.Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors[J].J Vasc Interv Radiol2008,9(10):1483-1489. [2]Kothary N, Weintraub JL, Susman J,et al. Transarterial Chemoembolization for Primary Hepatocellular Carcinoma in Patients at High Risk[J].J Vasc Interv Radiol.,2007, 18:1517-1526. [3]Sergio A, Cristofori C, Cardinr R, et al.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness[J].Am J Gastroenterol.2008,103(4):914-921. [4] Zhao Zenghu, Zhang Jianyu, Zhang Xiufang etc. Effect of TACE on primary hepatic carcinoma V EGF and MVD [J]。Chinese Journal of Misdiagnostics, 2007, 7(4):717-718. [5] Adriana S, Chiara C,Romilda C,etal.Transcatheter arterial chemoembolization (TACE)in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914–921. [6] Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma[J]. Cancer,2008,112(2):250-259. [7]Almhanna K,Kalmadi S, Pelley R,et al.Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach? [J].Oncology;2007, 21(9):1116-1122. [8]Pang RW, Poon RT.From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now[J].Oncology,2007,72 (Suppl)1:30-44. [9] Antoine H, Andrew HP, Himaja P,etal.Combination of Radiofrequency Ablation with Antiangiogenic Therapy for Tumor Ablation Efficacy: Study in Mice.Radiology 2007;244:464-470. [10]Thomas MB, Chadha R, Glover K,et al.Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma[J].Cancer,2007,110(5):1059-1067. [11]Liu L, Cao Y, Chen C, et al.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res,2006, 66(24):11851-11858. [12] Josep L, Sergio R, Vincenzo M,et al.Sorafenib in advanced hepatocellular carcinoma [J].N Engl J Med,2008,359(24):378-390. [13]Mahmood U.Can a clinically used chemoembolization vehicle improve transgene delivery? [J] Radiology,2006,240:619-620. [14]Kruskal JB,Goldberq SN.Emerging therapies for hepatocellular carcinoma: opportunities for radiologists[J].J Vasc Interv Radiol,2002,13(9 Pt 2):S253-258. [15] Hao Mingzhi, Lin Haizhen, Chen Qiang et al. Randomized controlled study of thalidomide combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J]. Cancer, 2007, 26(8): 861-865. [16]Feng Gansheng, Qi Xiuheng, Wu Zhenming, Liu Qi, Clinical observation of hepatic arterial infusion of endostar combined with interventional chemotherapy and embolization for advanced hepatocellular carcinoma[J]. Chinese Journal of Clinical Oncology, 2008, 35(1): 5-7. [17] Huang Ying, Deng Gang, Guo Jinhe, et al. Dynamic observation of plasma VEGF levels after treatment of primary hepatocellular carcinoma with intra-arterial endostatin combined with chemoembolization[J]. Cancer, 2008, 28(4): 357-359. [18]Kim YI,Chung JW,Park JH,et al.Intraarterial gene delivery in rabbit hepatic tumors: transfection with nonviral vector by using iodized oil emulsion[J].Radiology,2006,240:771-777. [19] Maataoui A, Qian J,Vossoughi D,Khan MF.Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model[J].Eur Radiol,2005,15(1):127–133. [20] Zhu AX,Blaszkowsky LS, Ryan DP.Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma[J].Journal of Clinical Oncology,2006,24(12):1898-1903. [21] Chen Fengsheng, Cui Yanzhi, Luo Rongcheng et al, Inhibiting Effect of Sorafenib Combined with Cis-platinum On Liver Cancer HepG2 Cells, Journal of Southern Medical University, 2008,28(9):1684-1687. [22] Richly H, Schultheis B, Adamietz IA.Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial[J].Eur J Cancer. 2008,18.[Epub ahead of print]. [23]Takimoto CH, Awada A.Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials[J].Cancer Chemother Pharmacol,2008,61(4):535-548. [24] Liu F,Tan G, Li J et al.Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice[J].Cancer Sci,2007,98(9):1381-1387. [25] Dal LL, D'hondt V, Awada A.Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors[J].Oncologist.,2008,13(8):845-858. [26] Julien N, Michel W, Jean MM,etal.Drug-eluting beads for liver embolization:concentration of doxorubicin in tissue and in beads in a pig model[J]. J Vasc Interv Radiol 2010; 21:259–267